Baxter Shares Plummet as Device Crisis Deepens
Published on 11/06/2025 at 11:17 | Redaktion boerse-global.de
The medical technology firm Baxter International finds itself navigating a severe corporate storm, with challenges extending far beyond disappointing quarterly earnings. At the heart of the turmoil lies the Novum IQ Large Volume Pump, an infusion device allegedly linked to patient safety risks. As attorneys assemble class-action lawsuits, investors are questioning the company’s ability to survive this escalating nightmare.
When Baxter reported its quarterly results in late October, the financial impact of its operational troubles became starkly clear. Although the company posted improved adjusted earnings, it fell short of revenue expectations and was compelled to downgrade its full-year forecast. The market reaction was brutal: shares collapsed by more than 14 percent, Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
